All Updates

All Updates

icon
Filter
Funding
NADMED raises EUR 3.5 million in Series A funding to expand internationally
Longevity Tech
Aug 22, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Today
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Today
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Today
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Yesterday
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Yesterday
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Yesterday
Partnerships
FinFit partners with Sunny Day Fund to offer emergency savings accounts
Financial Wellness Tools
Yesterday
Partnerships
KSP partners with Peak Technologies and Locus Robotics for warehouse automation
Logistics Tech
Yesterday
Longevity Tech

Longevity Tech

Aug 22, 2024

NADMED raises EUR 3.5 million in Series A funding to expand internationally

Funding

  • Finnish-based biotechnology company NADMED raised EUR 3.5 million (USD 3.9 million) in Series A funding led by Nordic Science Investments, with participation from Voima Ventures, University of Helsinki Funds, private European investors, and a grant from Business Finland.

  • The new funds will be used to expand NADMED's operations and development efforts for its nicotinamide adenine dinucleotide (NAD) measurement technology, enter the US and other international markets, and expand its operations and development efforts.

  • NADMED specializes in the development of blood testing technology for measuring NAD levels. Its proprietary method, developed from research at the University of Helsinki, is the first to measure all four bodily forms of NAD directly from fresh blood, providing rapid and accurate results. This breakthrough technology helps clinicians detect vitamin B3 deficiencies and offers more personalized treatments for age-related conditions such as metabolic disorders, cancer, and cardiovascular diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.